Rodbard, H.W., Lingvay, I., Reed, J., De La Rosa, R., Rose, L., Sugimoto, D., Araki, E., Chu, P.L., Fung, A., and Hirsch, I.B
Discussion In this study, we focused exclusively on FDA- and EMA-approved liposomal drug formulations currently on the market (five for passive loading systems, including Arikayce Kit, Visudyne, AmBisome, Mepact, and Exparel, and four for active loading systems, including Doxil, Myocet, Onivyde, and Vyxeos)
In clinical trials: Semaglutide: Approximately 7% discontinued due to adverse events Tirzepatide: Approximately 4-7% discontinued due to adverse events (dose dependent) Retatrutide: Approximately 6-10% discontinued due to adverse events (dose dependent) These rates are relatively close, suggesting that despite the differences in mechanism and side effect profiles, all three medications are tolerable for the vast majority of people who start them
Understanding the mechanisms, benefits, and possible side effects is crucial for anyone considering Semaglutide as part of their treatment plan.
&srotate=0)
